Gene Therapy & Arrhythmogenic Cardiomyopathy
Gene Therapy & Arrhythmogenic Cardiomyopathy
Tuesday, June 18 at 5:00 pm PT | 8:00 pm ET
This one-hour webinar targeted to physicians and medical professionals will focus on genetics, gene therapy and its role in Arrhythmogenic Cardiomyopathy (ACM).
Description
Dr. Parikh will focus on an overview of genetics and their role in ACM. Specifically, she will cover ACM disease physiology and particulars of RV structure, desmosomes, gap junctions, etc.
Dr. Pollman will focus on Tenaya Therapeutics’ gene therapy clinical trial in patients with ARVC caused by PKP2 gene mutation.
The Speakers
Victoria Parikh, MD is a clinician-scientist and Assistant Professor of Cardiovascular Medicine at Stanford Medicine. She cares for patients with and studies inherited (genetic) cardiovascular disease. She is the director of the Stanford Center for Inherited Cardiovascular Disease (SCICD). SCICD integrates clinical and basic science with the expert care of patients with genetic cardiovascular conditions (e.g., cardiomyopathies, arrhythmias and vascular diseases). Dr. Parikh’s own clinical practice and laboratory are focused on the genetics of cardiomyopathies and their associated arrhythmogenic substrates.
Matthew Pollman, MD, MS
Victoria Parikh, MD
Matthew Pollman, MD, MS is Senior Vice President, Clinical Development, Tenaya Therapeutics.
A cardiologist and molecular biologist by training, Dr. Pollman most recently served as Executive Vice President for NaviGate Cardiac Structures, Inc. Prior to this appointment, he served as the Chief Medical Officer for Juventas Therapeutics and was the Founding CEO, President and Chief Scientific Officer of CV Ingenuity, a clinical stage company acquired by Covidien. Prior to founding CV Ingenuity, he served as Medical Director, Research and Development, at Abbott Vascular and was the principal medical and scientific strategist and advisor for the R&D pipeline and Business Development portfolios.
He has served as a full-time faculty member at Harvard Medical School and Morehouse School of Medicine. He is the author of numerous peer-reviewed journal articles and is the past recipient of two investigator-initiated NIH NHLBI R01 grants in basic cardiovascular research.
This webinar is sponsored in part by Tenaya Therapeutics
